BioCryst Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 110,400 shares, and restricted stock units covering an aggregate of 51,300 shares, of BioCryst common stock. The options and RSUs were granted as of February 28, 2023 as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.85 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst presents new long-term, real-world data on ORLADEYO
- BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Needham upgrades BioCryst to Buy, sees selloff provide attractive entry